α-Hederin Alleviates Endoplasmic Reticulum Stress by Upregulating TRIM38 Expression, Thereby Inhibiting Hepatic Stellate Cell Activation and Liver Fibrosis
Open Access
- 5 April 2026
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 14 (4) , 829
Abstract
Objectives: This study aims to investigate the potential molecular mechanisms by which α-hederin modulates HSC activation to alleviate liver fibrosis. Methods: An in vitro model of liver fibrosis was established by inducing LX-2 cells with TGF-β1. These cells were then treated with α-hederin (10 μg/mL) before undergoing phenotypic analysis and molecular-level detection. A mouse model of liver fibrosis induced by CCl4 was established in vivo to further evaluate the expression levels of fibrosis markers, including TRIM38. Results: In TGF-β1-induced liver fibrosis in LX-2 cells, α-hederin treatment significantly inhibited HSCs activation, as evidenced by down-regulation of α-SMA and suppressed proliferation capacity. At the same time, α-hederin significantly reduced the levels of COL1A1, COL3A1, fibronectin, and MMP-2. Transcriptome sequencing analysis revealed that α-hederin treatment significantly upregulated TRIM38 expression. Differentially expressed genes (DEGs) were significantly enriched in endoplasmic reticulum stress-related pathways. TRIM38 up-regulation inhibits HSC activation and proliferation, reducing the expression of ERS marker proteins (GRP78, p-PERK, and CHOP); Co-IP experiments further confirmed that TRIM38 and GRP78 interact directly. Further rescue experiments demonstrated that TRIM38 knockdown significantly attenuated the inhibitory effects of α-hederin on these processes. In a CCl4-induced mouse model of liver fibrosis, α-hederin (4 mg/kg) significantly reduced the liver index and serum ALT and AST levels, improved histopathological damage to the liver, upregulated TRIM38 expression in liver tissue, and inhibited the endoplasmic reticulum stress response (ERS). Conclusions: α-hederin exerts its anti-fibrotic effect by upregulating TRIM38, thereby alleviating endoplasmic reticulum stress and ultimately inhibiting the activation and proliferation of HSCs.Keywords
Funding Information
- Key Laboratory of Infectious Diseases and Hepatology, Guizhou Medical University ([2024] fy006)
This publication has 47 references indexed in Scilit:
- The Role of the PI3K/Akt/mTOR Pathway in Atherosclerosis: Mechanisms, Therapeutic Potential, and Emerging Targeted TreatmentsCurrent Atherosclerosis Reports, 2025
- TRIM38 Suppresses the Progression of Colorectal Cancer via Enhancing CCT6A Ubiquitination to Inhibit the MYC PathwayAdvanced Science, 2025
- EMC10 modulates hepatic ER stress and steatosis in an isoform-specific mannerJournal of Hepatology, 2024
- Molecular mechanism of α-Hederin in tumor progressionBiomedicine & Pharmacotherapy, 2023
- α-Hederin induces human colorectal cancer cells apoptosis through disturbing protein homeostasisChemico-Biological Interactions, 2023
- Confirmatory biomarker diagnostic studies are not needed when transitioning from NAFLD to MASLDJournal of Hepatology, 2023
- Anticancer properties and mechanism insights of α-hederinBiomedicine & Pharmacotherapy, 2023
- Stress and Liver FibrogenesisThe American Journal of Pathology, 2023
- Tripartite motif 38 attenuates cardiac fibrosis after myocardial infarction by suppressing TAK1 activation via TAB2/3 degradationiScience, 2022
- The Power of Plasticity—Metabolic Regulation of Hepatic Stellate CellsCell Metabolism, 2020